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ABSTRACT
Objectives Chronic Obstructive Pulmonary Disease 
(COPD) is a progressive disease. Preventing deterioration 
of health status is therefore an important therapy goal. 
(Minimal) Clinically Important Differences ((M)CIDs) are 
used to interpret changes observed. It remains unclear 
whether (M)CIDs are similar for both deterioration and 
improvement in health status. This study investigates and 
compares these clinical thresholds for three widely-used 
questionnaires.
Design and setting Data were retrospectively analysed 
from an inhouse 3-week pulmonary rehabilitation (PR) 
randomised controlled trial in the German Klinik Bad 
Reichenhall (study 1), and observational research in Dutch 
primary and secondary routine clinical practice (RCP) 
(study 2).
Participants Patients with COPD aged ≥18 years (study 
1) and aged ≥40 years (study 2) without respiratory 
comorbidities were included for analysis.
Primary outcomes The COPD Assessment Test (CAT), 
Clinical COPD Questionnaire (CCQ) and St George’s 
Respiratory Questionnaire (SGRQ) were completed at 
baseline and at 3, 6 and 12 months. A Global Rating of 
Change scale was added at follow-up. Anchor-based 
and distribution-based methods were used to determine 
clinically relevant thresholds.
Results In total, 451 patients were included from PR and 
207 from RCP. MCIDs for deterioration ranged from 1.30 to 
4.21 (CAT), from 0.19 to 0.66 (CCQ), and from 2.75 to 7.53 
(SGRQ). MCIDs for improvement ranged from −3.78 to 
−1.53 (CAT), from −0.50 to −0.19 (CCQ), and from −9.20 
to −2.76 (SGRQ). Thresholds for moderate improvement 
versus deterioration ranged from −5.02 to −3.29 vs 3.89 
to 8.14 (CAT), from −0.90 to −0.72 vs 0.42 to 1.23 (CCQ), 
and from −15.85 to −13.63 vs 7.46 to 9.30 (SGRQ).
Conclusions MCID ranges for improvement and 
deterioration on the CAT, CCQ and SGRQ were somewhat 
similar. However, estimates for moderate and large change 
varied and were inconsistent. Thresholds differed between 
study settings.
Trial registration number Routine Inspiratory Muscle 
Training within COPD Rehabilitation trial: #DRKS00004609; 
MCID study: #UMCG201500447.
InTRODuCTIOn
The use of health status questionnaires 
is recommended by the Global initiative 
for Chronic Obstructive Lung Disease 
(GOLD) for the assessment, evaluation 
Strengths and limitations of this study
 ► Our study is the first dedicated investigation of (min-
imal) clinically important differences ((M)CIDs) for 
deterioration on chronic obstructive pulmonary dis-
ease (COPD) health status tools in comparison with 
thresholds for improvement.
 ► Our study used a combination of anchor-based 
and distribution-based methods to determine clini-
cally relevant thresholds for both deterioration and 
improvement.
 ► Our study investigated clinically relevant thresholds 
in two different study settings—pulmonary rehabil-
itation (PR) and routine clinical practice (RCP)—by 
using data from various follow-up periods to mini-
mise the possible impact of the recall period.
 ► Our study included a limited number of patients with 
deterioration after PR and during RCP, and a limited 
number of patients indicating moderate and large 
change in health status.
 ► Our study resulted in broad ranges and wide CIs for 
(M)CIDs of COPD health status tools, requiring possi-
bly larger sample sizes for more accuracy.
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and management of patients with chronic obstructive 
pulmonary disease (COPD).1 The COPD Assessment 
Test (CAT),2 the Clinical COPD Questionnaire (CCQ)3 
and the St George’s Respiratory Questionnaire (SGRQ)4 
are frequently used patient-reported health status tools 
important for clinical practice and scientific research,5 
especially since the burden of COPD is high worldwide.6 7 
Various studies have examined clinically relevant 
thresholds for change on the CAT, CCQ and SGRQ in 
order to be able to evaluate and interpret treatment 
effects.8–18 The minimal clinically important difference 
(MCID) is a parameter that quantifies this threshold. It 
has been defined as ‘the smallest difference in score, which 
patients perceive as beneficial and which would mandate a 
change in the patient’s management’.19 MCIDs are particu-
larly interesting for health status questionnaires, where a 
change in its score is not intuitively meaningful. Change 
exceeding the level of the MCID can be considered clini-
cally relevant, thus justifying therapy and help developing 
guidelines. It is pivotal that clinically relevant thresholds 
for change on a health status tool are rigorously studied 
and analysed carefully.
Most clinical studies that determine the MCID of 
patient-reported outcomes (PROs) are executed in the 
context of an intervention such as pharmacotherapy or 
pulmonary rehabilitation (PR). This usually results in an 
improvement in the patients’ health-related quality of life 
(HRQoL). MCIDs for improvement have thus been inves-
tigated; however, there is a lack of evidence for the MCIDs 
for deterioration.20 It remains unclear and debated on to 
what extent clinically relevant thresholds for improvement 
should be similar to those for deterioration.21–24 Certain 
studies outside the field of COPD have analysed the MCIDs 
of PROs and found evidence that values for improvement 
differed from deterioration.25–29 On the other hand, there 
is also evidence that thresholds might be similar.30 Inter-
preting worsening of HRQoL is of major importance, 
since one needs to differentiate between real worsening 
of patients’ status and random variations. Furthermore, 
the effects of therapy may also halt further deterioration 
especially for a progressive chronic disease like COPD. So 
no relevant worsening or a reduction in clinically relevant 
deterioration over time might also be considered a success 
of therapy and in clinical trials.31
In COPD health status, the estimated MCID for the 
CAT score is 2.00–3.00 units,11–15 20 for the CCQ score 
0.40–0.50 units8–13 20 and for the SGRQ score 4.00–8.00 
units.12 16–18 20 This is valid for improvement only, as 
there were too few patients with deterioration to inves-
tigate. There are currently no studies that specifically 
investigate clinically relevant thresholds for deterio-
ration on these PROs. It is however worrying that up 
to date, multiple studies included the MCIDs of these 
COPD health status instruments for improvement to 
interpret deterioration in clinical trials.32–34 This study 
therefore aims to determine and compare clinically rele-
vant thresholds for deterioration and improvement on 
the COPD health status questionnaires CAT, CCQ and 




This study was a retrospective analysis of data obtained 
from two prospective clinical trials. Study 1 was a 
secondary analysis of a subsample from the Routine 
Inspiratory Muscle Training within COPD Rehabilita-
tion (RIMTCORE) real-life randomised controlled trial 
in the Klinik Bad Reichenhall, Center for Rehabilita-
tion, Pulmonology and Orthopedics in Germany.12 35 
Patients were recruited on arrival in the clinic between 
February 2013 and July 2014. Participants were 
included if they had COPD GOLD II–IV, were aged ≥18 
years and gave informed consent.12 35 Exclusion criteria 
were the presence of other respiratory comorbidities 
(eg, bronchiectasis, asthma, history of bronchial carci-
noma, sarcoidosis, tuberculosis) or alpha-1-antitrypsin 
deficiency.
Study 2 (MCID study) was an observational trial of 
patients with COPD GOLD I–IV aged ≥40 years without 
other respiratory comorbidities or alpha-1-antitrypsin 
deficiency. Patients were recruited from Dutch primary 
and secondary RCP between September 2015 and 
September 2016. Patients were approached via multiple 
general practices, hospitals and the Dutch patient lung 
federation.
Patient and public involvement
In both studies, patients and the public have not actively 
been involved during the design of the study nor in the 
assessment of the burden. Summary results are dissemi-
nated to participating patients after completion.
Study design and data collection
Patients in study 1 participated in an intensive, 3-week, 
full-day inpatient PR programme tailored to the patient’s 
individual needs. Details have been presented previ-
ously.12 35 Patient descriptives and postbronchodilator 
spirometry were collected at baseline and discharge 
in the clinic. Patients in study 2 received routine care 
from their physician according to national treatment 
guidelines. Evaluation of health status over a 12-month 
period was the primary measurement outcome. Patient 
descriptives and spirometry data were obtained at base-
line. Spirometry results were obtained via the including 
physician after approval of the participant.
The primary outcomes selected from both prospec-
tive studies for this retrospective analysis were the 
CAT (no recall period), CCQ (weekly version) and 
SGRQ (monthly version). In study 1, these question-
naires were collected at baseline, at PR discharge and 
during follow-up at 3, 6, 9 and 12 months. Baseline 
and discharge measurements were taken in the clinic, 
where patients were blinded to their baseline scores. 
Follow-up questionnaires were sent by mail. In study 
2, all questionnaires were sent by mail and scored at 
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home at baseline and at 3, 6 and 12 months. For this 
retrospective analysis, baseline and follow-up scores at 
3, 6 and 12 months were included, to allow for sufficient 
time for deterioration in HRQoL, to include various 
time periods of measurement and to allow for compar-
ison between both study settings.
The CAT is an eight-item, one-dimensional scale 
with item scores ranging 0–5 (0: no impairment; 5: 
maximum impairment) and a total score summing up 
to a maximum of 40.2 The CCQ consists of 10 items 
scoring 0–6 (0: no impairment; 6: maximum impair-
ment).3 The items cover the domains symptoms (four 
items), functional status (four items) and mental status 
(two items). Total and domain scores on the CCQ derive 
from adding up relevant item scores and dividing this 
by the number of items. The SGRQ has 50 items classi-
fied into the domains symptoms (8 items), activities (16 
items) and impact (26 items).4 Domain and total SGRQ 
scores can range from 0 to 100 (0: no impairment; 100: 
maximum impairment). A 15-point Likert scale anchor 
question (Global Rating of Change, GRC) was scored 
retrospectively by the patient at each follow-up visit 
in both data sets. The GRC required patients to assess 
their COPD health status compared with baseline. The 
answers were marked on a scale from −7 to +7, ranging 
from very much worse to very much better and 0 equalling 
no change.36 37
Study methods
All change scores for the total scores of the CAT, CCQ 
and SGRQ were calculated as the difference between 
baseline and the respective follow-up visit (3, 6 and 12 
months). Negative change on all questionnaires repre-
sented improvement, and positive change deteriora-
tion. First, in the anchor-based approach, changes on 
the health status instruments were classified using the 
corresponding score on the GRC. Scores of 0 and ±1 
on the GRC indicated no change; scores of ±2 and ±3 
represented a minimal improvement/deterioration; scores 
of ±4 and ±5 were summarised as a moderate improve-
ment/deterioration; and scores of ±6 and ±7 indicated a 
large improvement/deterioration.36 37 MCID estimates for 
Figure 1 Forest plot of clinically relevant thresholds for improvement and deterioration on the COPD Assessment Test. 
Data are presented as mean estimates (squares) including 95% CI (horizontal lines). Estimates from the half SD analysis are 
represented as single squares. Weighted mean estimates are presented as larger diamonds. Data are separated as minor, 
moderate and large improvement thresholds (left half), versus minor and moderate deterioration thresholds (right half). COPD, 
chronic obstructive pulmonary disease; PR, pulmonary rehabilitation; RCP, routine clinical practice. T0, baseline measurement; 
T3, 3-month follow-up; T6, 6-month follow-up; T12, 12-month follow-up. 
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both improvement and deterioration on the CAT, CCQ 
and SGRQ were calculated as the mean change scores 
including 95% CI of those patients indicating a minimal 
improvement/deterioration (±2 and ±3) on the GRC for 
each follow-up visit, verifying normality of distribution. 
Mean estimates including 95% CI were determined in 
a similar way for patients indicating no change (GRC 
0 and ±1), moderate change (GRC ±4 and ±5) and 
large change (GRC ±6 and ±7). Second, the distribu-
tion-based method half SD (0.5 SD) of the change score 
was calculated for improved and deteriorating health 
status patients at respective follow-up visits.38
Data analysis
Data analysis was performed using SPSS V.24.0. Descrip-
tives were evaluated at baseline for either frequencies 
with percentages (%), mean with SD or median with 
range. This was depending on the variable character-
istics and/or normality of distribution. Health status 
data on the CCQ, CAT and SGRQ were evaluated at 
baseline (T0), 3 months (T3), 6 months (T6) and after 
12 months (T12). Normality of distribution was veri-
fied using skewness and kurtosis. Values between −1 
and +1 were considered indicative for normality. Data 
were checked for floor and ceiling effects, defined as 
over 15% of patients scoring in the lowest and highest 
10% of the maximum scale range.39 Mean and SD (or 
median and range) were calculated at each measure-
ment moment for all patients, as well as specifically 
for patients with improved and deteriorated health 
status scores. Baseline scores were compared between 
improving and deteriorating patients, and tested using 
independent t-tests after verifying normality of distri-
bution. Baseline scores were compared between both 
data sets (PR vs RCP) using independent t-tests, Mann-
Whitney U tests or χ2 tests depending on the variable 
characteristic and/or normality of distribution. Health 
status change scores were all calculated in comparison 
with baseline. Follow-up scores were compared with 
baseline to test for significance of change using paired 
t-tests verifying normality of distribution.
Figure 2 Forest plot of clinically relevant thresholds for improvement and deterioration on the Clinical COPD Questionnaire. 
Data are presented as mean estimates (squares) including 95% CI (horizontal lines). Estimates from the half SD analysis are 
represented as single squares. Weighted mean estimates are presented as larger diamonds. Data are separated as minor, 
moderate and large improvement thresholds (left half), versus minor and moderate deterioration thresholds (right half). COPD, 
chronic obstructive pulmonary disease; PR, pulmonary rehabilitation; RCP, routine clinical practice; T0, baseline measurement; 
T3, 3-month follow-up; T6, 6-month follow-up; T12, 12-month follow-up. 
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In order to determine clinically relevant thresholds 
for change, first correlations between the GRC and 
the CCQ, CAT and SGRQ were assessed using Pearson 
or Spearman correlation coefficients depending on 
normality of distribution. Correlations needed to be 
≥0.30 (preferably ≥0.50) to be eligible as anchor.22 
Correlations were assessed between GRC and question-
naire change scores, and between GRC, baseline and 
follow-up questionnaire score to assess for a possible 
response shift. Next, participants were categorised 
according to their GRC score at each follow-up. Mean 
changes (95% CI) for each respective category were 
determined to define thresholds for clinically relevant 
change. Significance of change for each GRC class at 
the respective follow-up visit was compared with base-
line and assessed with paired t-tests verifying normality 
of the data. Last, the 0.5 SD of the change score was 
determined for patients with improved and deterio-
rating health status change scores separately at each 
follow-up. Thresholds were compared between both 
study settings (PR vs RCP).
An absolute overall weighted mean MCID estimate 
for both improvement and deterioration was calculated 
at the end by multiplying the number of observations 
(n) at each follow-up visit times the MCID estimate for 
that period. The sum was divided by the total number 
of observations. Anchor-based and distribution-based 
approaches had similar weights. Estimates for improve-




Study 1 included 451 patients with completed baseline 
data (table 1).12 35 During follow-up 355 patients (78.7%) 
had completed data at T3, 319 patients (70.7%) at T6 
and 309 patients (68.5%) at T12. During the 12-month 
follow-up, 8 patients passed away, 41 dropped out at 
own request, and a varying number of non-response was 
present. Study 2 included 207 patients with full baseline 
data (table 1), of whom 201 (97.1%) completed T3, 186 
(89.9%) T6 and 177 (85.6%) T12. Four patients died, 
12 patients discontinued at own request, and a various 
number of non-response was present.
There were no significant baseline differences 
between completers and non-completers of the 
12-month follow-up in both studies, except that signifi-
cantly more women (28.4%) compared with men 
(10.0%) did not complete the follow-up during RCP. 
Significant differences in age, forced expiratory volume 
in 1 s percentage predicted (FEV1%pred) and health 
status were observed between both studies (table 1).
health status scores for improvement and deterioration
In study 1 and study 2, CAT, CCQ and SGRQ total 
were normally distributed at baseline and follow-up. 
Completed pairs of change scores (follow-up vs 
baseline) were included (pairwise deletion). Floor and 
ceiling effects were negligible. Mean health status base-
line scores were significantly different for PR and RCP 
(table 1). Overall, 58%–59% of patients had improved 
health status scores (negative change) at T12 after PR, 
compared with 44%–47% during RCP (table 2). After 
PR mean changes observed on the CAT questionnaire 
at T12 were −5.45±4.66 for improvers and 5.47±4.22 for 
patients who deteriorated; on the CCQ questionnaire 
−0.87±0.72 for improvement and 0.83±0.62 for deteri-
oration; and on the SGRQ questionnaire −13.83±10.43 
Table 1 Baseline patient characteristics




n 451 207 –
Age (years)† 57.87±6.56 66.69±7.91 <0.001*
Gender 
(male)‡
293 (65.0) 121 (58.5) 0.507
FEV1%pred† 50.40±15.11 57.06±21.96 0.001*
GOLD I‡ – 35 (17.4) 0.199 
GOLD II 227 (50.3) 80 (39.8) 
GOLD III 176 (39.0) 61 (30.3) 
GOLD IV 48 (10.6) 25 (12.4)
Smoking pack 
years† 
40 (30–50) 37.5 (22.50–
51.25)
0.081
CAT total† 20.23±7.33 18.32±7.22 0.002*










2.86±1.74 1 (0–1.50) <0.001*










mMRC† 2 (2–4) 1 (1–2) <0.001*
*Significance testing at p<0.05 using unpaired t-tests, Mann-
Whitney U tests or χ2 tests.
†Data are expressed as mean±SD or median (IQR).
‡Data are expressed as frequencies (% of total).
 CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; 
COPD, chronic obstructive pulmonary disease; FEV1%pred, forced 
expiratory volume in 1 s % predicted; GOLD, Global Initiative 
for Chronic Obstructive Lung Disease; mMRC, modified Medical 
Research Council Dyspnea Scale; n, number of patients; PR, 
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Table 2 Health status baseline and change scores for all, improved and deteriorated patients during PR and RCP
Change after 3 
months n





  All patients PR −1.44* (−2.16 to 
−0.71)
354 −0.91* (−1.66 to 
−0.16)
319 −0.89* (−1.68 to 
−0.11)
309
  Improvement 
PR
−5.45±4.57 227 (64.1) −5.49±4.33 184 (57.7) −5.45±4.66 180 (58.3)
  Deterioration 
PR
5.75±4.20 127 (35.9) 5.33±4.10 135 (42.3) 5.47±4.22 129 (41.7)
  All patients 
RCP
0.30 (−0.42 to 
+1.02)
201 0.18 (−0.53 to 
+0.90)
186 0.14 (−0.59 to 
+0.87)
177
  Improvement 
RCP
−4.04±3.33 102 (50.7) −4.64±3.05 81 (43.5) −4.53±3.15 79 (44.6)
  Deterioration 
RCP
4.23±3.66 83 (41.3) 3.76±2.88 91 (48.9) 3.88±2.59 86 (48.6)
  No change 
RCP
– 16 (8.0) – 14 (7.5) – 12 (6.8)
CCQ total
  All patients PR −0.26* (−0.37 to 
−0.15)
355 −0.11 (−0.23 to 
+0.01)
319 −0.16* (−0.28 to 
−0.04)
309
  Improvement 
PR
−0.88±0.71 225 (63.4) −0.84±0.68 181 (56.7) −0.87±0.72 180 (58.3)
  Deterioration 
PR
0.82±0.68 130 (36.6) 0.84±0.67 138 (43.3) 0.83±0.62 129 (41.7)
  All patients 
RCP
0.00 (−0.09 to 
+0.08)
200 0.00 (−0.10 to 
+0.10)
185 −0.02 (−0.12 to 
+0.09)
174
  Improvement 
RCP
−0.45±0.37 96 (48.0) −0.52±0.51 87 (47.0) −0.54±0.54 77 (44.3)
  Deterioration 
RCP
0.50±0.38 89 (44.5) 0.56±0.46 80 (43.2) 0.51±0.39 88 (50.6)
  No change 
RCP
– 15 (7.5) – 18 (9.7) – 9 (5.2)
SGRQ total
  All patients PR −5.35* (−6.92 to 
−3.78)
350 −4.85* (−6.47 to 
−3.23)
312 −3.94* (−5.67 to 
−2.21)
306
  Improvement 
PR
−13.11±9.65 237 (67.7) −13.51±9.88 193 (61.9) −13.83±10.43 180 (58.8)
  Deterioration 
PR
10.93±10.18 113 (32.3) 8.19±8.92 119 (38.1) 10.19±8.94 126 (41.2)
  All patients 
RCP
−0.52 (−1.77 to 
+0.73)
198 −1.34 (−2.76 to 
+0.07)
184 −0.87 (−2.60 to 
+0.86)
174
  Improvement 
RCP
−6.61±5.58 97 (49.0) −7.91±5.52 75 (40.8) −7.74±9.51 81 (46.6)
  Deterioration 
RCP
7.36±5.49 101 (51.0) 7.78±6.18 108 (58.7) 8.46±7.06 92 (52.9)
  No change 
RCP
– 0 – 1 (0.5) – 1 (0.6)
Change was calculated compared with baseline. Negative change represents improvement for CAT, CCQ and SGRQ. Change scores for all 
patients reported as mean (95% CI). Change scores for improvement and deterioration are presented as mean±SD.
*Paired t-tests were significant at p<0.05 testing follow-up versus baseline measurements.
CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; n, number of patients; PR, 
pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St George’s Respiratory Questionnaire.
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for improvers and 10.19±8.94 for patients who deterio-
rated (table 2). For RCP, these estimates were for the 
CAT −4.53±3.15 for improvement and 3.88±2.59 for 
deterioration; for the CCQ −0.54±0.54 for improvement 
and 0.51±0.39 for deterioration; and for the SGRQ 
−7.74±9.51 for improvement and 8.46±7.06 for deteri-
oration (table 2).
There were no baseline differences in terms of age, 
gender and GOLD classification between patients with 
improved health status and those who deteriorated at 
T12 in both studies. Patients with a worse (read higher) 
CAT, CCQ or SGRQ baseline score prior to PR had 
significantly more improved health status after 1 year. 
Patients who improved during RCP had a significantly 
better baseline FEV1%pred.
Clinically important improvement versus deterioration
Significant correlations between the health status change 
scores and the GRC ranged, respectively, for study 1 from 
−0.33 to −0.41 (CAT), from −0.42 to −0.47 (CCQ), and from 
−0.48 to −0.54 (SGRQ) (table 3). These ranges were for study 
2, respectively, from −0.29 to −0.37, from −0.38 to −0.48, and 
from −0.35 to −0.44. GRC scores had stronger correlations 
with the respective follow-up health status score compared 
with baseline and change scores for both studies.
Tables 4–6 and figures 1–3 present the clinically 
relevant thresholds for minimal, moderate and large 
changes on the CAT, CCQ and SGRQ during PR and 
RCP. On the CAT anchor-based and distribution-based 
estimates ranged from −2.80 to −2.17 (weighted mean 
−2.51) for minimal improvement and from 2.05 to 4.21 
for minimal deterioration (weighted mean 2.76) during 
PR (table 4, figure 1). These ranges were, respectively, 
from −3.78 to −1.53 (weighted mean −2.49) and from 
1.30 to 1.97 (weighted mean 1.65) during RCP. On the 
CCQ minimal clinically important improvements were 
determined at −0.50 to −0.34 (weighted mean −0.40) 
for PR and at −0.44 to −0.19 (weighted mean −0.33) 
for RCP (table 5, figure 2). These thresholds for dete-
rioration were from 0.31 to 0.66 (weighted mean 0.43) 
during PR and from 0.19 to 0.46 (weighted mean 0.30) 
during RCP. On the SGRQ estimates ranged from −9.20 
to −4.83 (weighted mean −6.74) for minimal improve-
ment and from 4.46 to 7.52 for minimal deterioration 
(weighted mean 5.31) during PR (table 6, figure 3). 
These ranges were, respectively, from −4.76 to −2.76 
Figure 3 Forest plot of clinically relevant thresholds for improvement and deterioration on the St George’s Respiratory 
Questionnaire. Data are presented as mean estimates (squares) including 95% CI (horizontal lines). Estimates from the half SD 
analysis are represented as single squares. Weighted mean estimates are presented as larger diamonds. Data are separated as 
minor, moderate and large improvement thresholds (left half), versus minor and moderate deterioration thresholds (right half). 
PR, pulmonary rehabilitation; RCP, routine clinical practice; T0, baseline measurement; T3, 3-month follow-up; T6, 6-month 
follow-up; T12, 12-month follow-up. 
 o
n




pen: first published as 10.1136/bmjopen-2018-025776 on 28 June 2019. Downloaded from 
8 Alma HJ, et al. BMJ Open 2019;9:e025776. doi:10.1136/bmjopen-2018-025776
Open access 
(weighted mean −4.06) and from 2.75 to 7.53 (weighted 
mean 4.78) during RCP.
DISCuSSIOn
Summary of main findings
Using both anchor-based and distribution-based 
methods, the weighted MCIDs for improvement and dete-
rioration on the CAT were, respectively, −2.51 vs 2.76 
during PR, and −2.49 vs 1.65 during RCP. These thresh-
olds for improvement and deterioration on the CCQ 
were, respectively, −0.40 vs 0.43 during PR and −0.33 
vs 0.30 during RCP. MCIDs for the SGRQ were, respec-
tively, −6.74 vs 5.31 during PR and −4.06 vs 4.78 during 
RCP for improvement and deterioration. Estimates for 
minimal clinically important improvement and deteri-
oration were overall somewhat similar; however, abso-
lute MCIDs differed between PR and RCP. Thresholds 
for moderate and large improvement and deterioration 
differed from each other, as well as between study 
settings.
Interpretation of findings
Little evidence exists whether MCIDs for improvement 
are similar for deterioration.21 23 40 Jaeschke et al19 were 
the first to determine the MCID of a health status tool 
using a 15-point GRC combining both improved and 
deteriorated patients with COPD into one group of 
minimally changed participants. Juniper et al37 elabo-
rated on this by separating minimally improved patients 
from deterioration in asthma, but only a limited number 
of patients indicated deterioration and no conclusions 
on the MCID of deterioration were drawn. Outside the 
field of COPD, Crosby et al and de Vet et al21 40 stated 
that some studies demonstrated that a smaller MCID for 
improvement was required compared with deteriora-
tion. The current study does not confirm this, although 
MCIDs seemed smaller for RCP patients compared 
with PR. Patients experienced more change (hence 
larger absolute MCIDs) during intervention, possibly 
as a result of treatment. In RCP, smaller changes may 
be noted and regarded as relevant for the patient. 
Up to now it remains unclear, whether the reported 
differences between PR and RCP are a rehab-specific 
finding or generally as a result of intervention. Overall, 
the absolute values for the MCIDs for improvement 
versus deterioration did not seem to differ much here, 
with the exception of the SGRQ during PR. 
The ranges found in this study for the MCID of the 
CAT (improvement −3.78 to −1.53; deterioration 1.30 to 4.21) 
matched with estimates found in other studies.11–15 20 Two 
Table 3 Correlations between health status (change) scores and the GRC
GRC T3–T0 GRC T6–T0 GRC T12–T0
PR (n=355) RCP (n=201) PR (n=319) RCP (n=186) PR (n=309) RCP (n=177)
CAT change 
score
−0.33* −0.29* −0.40* −0.30* −0.41* −0.37*
CAT T0 −0.31* −0.11 −0.25* −0.22* −0.34* −0.22*
CAT T3 −0.56* −0.31* −0.50* −0.31* −0.50* −0.33*
CAT T6 – – −0.55* −0.40* −0.59* −0.34*
CAT T12 – – – – −0.64* −0.48*
CCQ change 
score
−0.42* −0.38* −0.44* −0.40* −0.47* −0.48*
CCQ T0 −0.26* −0.14* −0.19* −0.22* −0.29* −0.23*
CCQ T3 −0.61* −0.35* −0.52* −0.26* −0.54* −0.33*
CCQ T6 – – −0.56* −0.43* −0.59* −0.39*
CCQ T12 – – – – −0.66* −0.51*
SGRQ change 
score
−0.48* −0.35* −0.51* −0.33* −0.54* −0.44*
SGRQ T0 −0.28* −0.13 −0.24* −0.20* −0.32* −0.22*
SGRQ T3 −0.62* −0.29* −0.56* −0.25* −0.58* −0.28*
SGRQ T6 – – −0.61* −0.35* −0.62* −0.35*
SGRQ T12 – – – – −0.69* −0.51*
Data reported as Pearson or Spearman correlation coefficients between the health status (change) scores and the GRC anchor question. 
Correlations ≥0.50 are highlighted bold.
*Correlations are significant at p<0.05.
CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; GRC, Global Rating of 
Change; n, number of patients; PR, pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St George’s Respiratory Questionnaire; T0, 
baseline measurement; T3, 3-month follow-up; T6, 6-month follow-up; T12, 12-month follow-up.
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studies used a patient-assessed GRC to estimate the MCID 
of the CAT.14 15 However, no results were reported for 
worsened patients or the numbers of patients were too 
few. Other anchor-based methods suggested that a change 
of one point on the CAT might represent the MCID for 
deterioration.14 The weighted thresholds for minimal clin-
ically relevant improvement (−2.51 in PR and −2.49 in RCP) 
seemed somewhat comparable with the ones for deteriora-
tion (2.76 in PR and 1.65 in RCP) in the current study, except 
for deterioration during RCP. As CAT allows only integer 
scores,2 a change of three points seems a valid threshold for 
improvement and deterioration, although the MCID for 
deterioration in RCP could be closer to two points. Thresh-
olds for moderate improvement (−4.23 in PR) and deterio-
ration (7.06 in PR and 3.89 in RCP) turned out less similar. 
The number of patients moderately deteriorating was low 
and differences were observed between both study settings. 
Moderate change might be experienced with a change on 
the CAT score of four to seven points. Two previous studies 
suggested that a cut-off point of four points was identified 
for acute HRQoL deterioration in clinical practice.41 42 
This would match our estimates for moderate change. The 
number of patients with a large change was too low with 
wide CIs to enable valid conclusions.
Regarding the CCQ, the MCID ranges found for both 
improvement (−0.50 to −0.19) and deterioration (0.19–0.66) 
overlapped each other in absolute sense, indicating that esti-
mates for improvement and deterioration may be similar. 
However, differences were noted between PR (±0.40) and 
RCP (±0.30) for both minimal improvement and deterio-
ration. These estimates for the MCID matched with earlier 
evidence.8–13 One other study used a GRC to determine the 
MCID of the CCQ.8 Unfortunately, no data were available 
on worsening patients. Thresholds for moderate change on 
the CCQ were broad (±0.62 to ±1.23). Few patients experi-
enced large changes, but estimates for both types of MCID 
from both study settings were approximately one point.
Minimal thresholds for improvement (−9.20 to −2.76) 
and deterioration (2.75–7.53) on the SGRQ overlapped 
each other, although more variation was present here. 
A change of approximately four to seven points for both 
improvement and deterioration seemed to be the minimal 
clinically important threshold in the current study. The 
MCID for improvement during PR (−6.74) was larger than 
for deterioration (5.31); however, CIs for deterioration were 
wide. Estimates for the thresholds during RCP (4–5 points) 
were smaller compared with PR (5–7 points). Moreover, 
the distribution-based estimates turned out smaller than 
the anchor-based estimates, lowering the absolute weighted 
MCIDs. Thresholds for moderate improvement and deteri-
oration in the current study were not very similar, ranging 
absolutely from 7.46 to 16.06 points. Estimates for clinically 
relevant large HRQoL improvement on the SGRQ ranged 
from −20 to −18 points for PR and RC, but too few patients 
were included to draw valid conclusions.
The SGRQ MCID matched to some extent with previous 
results.12 16–18 20 Jones et al16 18 published a threshold of 
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clinical practice. Interestingly, most results in our current 
study suggest a larger MCID, although estimates from RCP 
included this four-point estimate. The estimate by Jones et 
al was based on a study using patient preference-based tech-
niques in COPD by applying a five-point patients’ judge-
ment of treatment efficacy (salmeterol). This MCID of four 
points was valid for the group of patients that experienced 
effective treatment. In addition, a clinicians’ five-point GRC 
was scored, resulting in an MCID of four points. Clinicians’ 
and patients’ ratings are however not necessarily similar.43
Strengths and limitations of the current study
This retrospective analysis of two prospective studies was the 
first to investigate clinically relevant thresholds for minimal, 
moderate and large changes in COPD health status 
comparing both improvement and deterioration using a 
triangulation of both anchor-based and distribution-based 
methods. There were sufficient correlations between 
the GRC and respective health status questionnaires as 
required,22 although they were still only weak to moderate. 
It should be noted that correlations were stronger with the 
follow-up score compared with the baseline and/or change 
score, possibly due to a response shift. Another strength is 
that multiple follow-up visits were included to limit possible 
influence of the period of measurements on the MCID and 
recall bias.21 24 Moreover, this study investigated clinically 
relevant thresholds for both PR and RCP, improving its clin-
ical application and external validity.
Although this is the first study to investigate thresholds 
for clinically relevant deterioration, still a limited number 
of patients indicated deterioration in HRQoL after PR and 
during RCP. This is a major limitation lowering the statis-
tical power of the analysis, especially since sample size calcu-
lations were not based on the separate GRC categories. A 
second limitation is that the found thresholds demon-
strate broad ranges with wide CIs, limiting its accuracy and 
requiring a larger sample size than our current studies had. 
Third, it should be taken into account that anchor-based 
and distribution-based approaches each has its own rele-
vance, either based on clinical retrospective assessments or 
statistical parameters. It is recommended to combine both 
methods in measuring an instrument’s MCID22; however, 
estimates were rather different between these methods.
Implications for future research and clinical practice
Patients with COPD tend to have worsening HRQoL over 
time; hence, MCIDs for deterioration have an important 
implication for clinical practice.44 45 Clinicians and 
researchers should be able to judge whether groups of 
patients were really worsening over time or that change 
observed was subject to random fluctuation. Preventing 
clinically relevant deterioration in HRQoL by means of 
therapy is thus an important goal too. Ideally, more research 
is needed to validate our thresholds for clinically relevant 
deterioration on the CAT, CCQ and SGRQ, for instance in 
studies of other kinds of interventions than PR. One cannot 
directly transform the thresholds for improvement into 
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has found differences. However, in the current study, the 
estimates turned out rather similar with differing MCIDs 
between studies. Setting could thus potentially impact the 
MCID, implying that the results in the current study do not 
necessarily need to be valid in other settings too.
COnCluSIOnS
Determining deterioration in HRQoL is of importance, 
since one needs to differentiate between real worsening of 
patients’ status and random variations. In this study, esti-
mates for clinically relevant thresholds for improvement and 
deterioration were somewhat similar, but differed between 
PR and RCP. We would recommend using cut-points of 
CAT ≥3 (intervention), CAT ≥2 (RCP), CCQ ≥0.40 (inter-
vention), CCQ ≥0.30 (RCP), SGRQ ≥6 (intervention) and 
SGRQ ≥5 (RCP) for both minimal improvement and dete-
rioration. Thresholds for, respectively, moderate and large 
changes should be further explored, but could approxi-
mately be in the range of, respectively, 4–5 and 5–6 for CAT, 
0.80 and 1.00 for CCQ, and 10–15 points and 15–20 points 
for SGRQ.
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